Acamprosate: A Review of Its Use in Alcohol Dependence
The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Abstract
Acamprosate (Campral(®), Aotal(®), Regtect(®)) is one of a limited number of pharmacological treatment options approved as an adjunct to psychosocial interventions to facilitate the maintenance of abstinence in alcohol-dependent patients. It has been used in Europe, the USA and other countries for many years and was recently approved for this indication in Japan. In several randomized, double-blind, placebo-controlled trials (without active comparators), acamprosate in conjunction with psychosocial therapy for 3-12 months was generally significantly better than placebo plus psychosocial interventions in improving various key outcomes, including the proportion of patients who maintained complete abstinence from alcohol (complete abstinence rate), the mean cumulative abstinence duration, the percentage of alcohol-free days and the median time to first drink. Acamprosate as an adjunct to psychosocial interventions also demonstrated efficacy in some randomized, active-comparator trials of similar duration. Although results were not always consistent across individual trials, overall findings were generally favourable for acamprosate in a recent meta-analysis, which showed that alcohol-consumption outcomes were similarly improved with acamprosate or naltrexone. Acamprosate is generally well tolerated, has a low propensity for drug interactions and may be used without dosage adjustment in patients with mild to moderate hepatic impairment, although dosage adjustments or contraindica…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Anton, R. F., O’Malley, S. S., Ciraulo, D. A., Cisler, R. A., Couper, D., Donovan, D. M., Gastfriend, D. R., Hosking, J. D., Johnson, B. A., LoCastro, J. S., et al. (2006) · JAMA · doi:10.1001/jama.295.17.2003 · Cited by 1,930 · cited 4×
“In the largest trial (COMBINE), 1383 patients from 11 US sites were randomized to nine possible treatment groups, of which four included medication without a combined behavioural intervention (CBI), four included medication with CBI and one included only CBI (no pills) [42].”
BackgroundMethodResultInfluentialJonas, D. E., Amick, H. R., Feltner, C., Bobashev, G., Thomas, K., Wines, R., Kim, M. M., Shanahan, E., Gass, C. E., Rowe, C. J., et al. (2014) · JAMA · doi:10.1001/jama.2014.3628 · Cited by 923 · cited 5×
“Overall, results were generally favourable for acamprosate in a recent systematic review and meta-analysis of pharmacotherapy for alcohol use disorders in outpatient settings that included 22 placebo-controlled trials with acamprosate, 44 with naltrexone and 4 with disulfiram [28].”
InfluentialThe clock gene Per2 influences the glutamatergic system and modulates alcohol consumption
Spanagel, R., Pendyala, G., Abarca, C., Zghoul, T., Sanchis-Segura, C., Magnone, M. C., Lascorz, J., Depner, M., Holzberg, D., Soyka, M., et al. (2005) · Nature Medicine · doi:10.1038/nm1163 · Cited by 594 · cited 1×
“Acamprosate has been shown to attenuate hyperglutamatergic activity and reduce ethanol consumption in mice that were drinking excessive quantities of ethanol [17, 18], and it reduced glutamate levels (assessed by magnetic resonance spectroscopy) in the brains of alcohol-dependent patients who had been detoxified [19].”
BackgroundHelping Patients Who Drink Too Much: A Clinician's Guide: (495492006-001)
US Department of Health and Human Services; National Institutes of Health; National Institute on Alcohol Abuse and Alcoholism (2005) · PsycEXTRA Dataset · doi:10.1037/e495492006-001 · Cited by 589
Relapse Prevention by Acamprosate: Results From a Placebo-Controlled Study on Alcohol Dependence
Sass, H. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830080023006 · Cited by 479 · cited 3×
“45 days; p-value not reported), which was also a co-primary endpoint [39].”
BackgroundMaisel, N. C., Blodgett, J. C., Wilbourne, P. L., Humphreys, K., & Finney, J. W. (2013) · Addiction · doi:10.1111/j.1360-0443.2012.04054.x · Cited by 470
Acamprosate for alcohol dependence
Rösner, S., Hackl-Herrwerth, A., Leucht, S., Lehert, P., Vecchi, S., & Soyka, M. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004332.pub2 · Cited by 412
Kiefer, F., Jahn, H., Tarnaske, T., Helwig, H., Briken, P., Holzbach, R., Kämpf, P., Stracke, R., Baehr, M., Naber, D., et al. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.92 · Cited by 400 · cited 2×
“Most were also double-blind, placebocontrolled trials [42, 43, 45, 47, 48], although two studies used an open-label design, in part, because patients in one of the treatment arms received disulfiram, and patients’ awareness that they are taking disulfiram is an important factor in its effectiveness [44, 46].”
BackgroundResultHelping patients who drinks too much. A Clinician’s Guide
Agabio, R., Fantozzi, F., & Tossicodipendenze, C. E. D. R. M. D. (2006) · UNICA IRIS Institutional Research Information System (University of Cagliari) · Cited by 391
Comparison of acamprosate and placebo in long-term treatment of alcohol dependence
Whitworth, A. B., Oberbauer, H., Fleischhacker, W. W., Lesch, O. M., Walter, H., Nimmerrichter, A., Platz, T., Fischer, F., & Potgieter, A. (1996) · The Lancet · doi:10.1016/s0140-6736(96)91682-7 · Cited by 320 · cited 3×
“tive abstinence duration at the end of follow-up [38, 40].”
BackgroundDOUBLE-BLIND RANDOMIZED MULTICENTRE TRIAL OF ACAMPROSATE IN MAINTAINING ABSTINENCE FROM ALCOHOL
(1995) · Alcohol and Alcoholism · doi:10.1093/oxfordjournals.alcalc.a045720 · Cited by 273 · cited 5×
“In addition, acamprosate was associated with statistically significant advantages over placebo for the mean cumulative abstinence duration in longer-term trials where this endpoint was considered a secondary outcome [38, 40].”
BackgroundInfluentialUpdate on neuropharmacological treatments for alcoholism: Scientific basis and clinical findings
Johnson, B. A. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.08.005 · Cited by 264 · cited 2×
“In general, clinical outcomes are poor when drug therapy is not used to enhance the effects of psychosocial interventions, with up to 70 % of patients resuming alcohol consumption within 1 year [4].”
BackgroundChick, J. (2000) · Alcohol and Alcoholism · doi:10.1093/alcalc/35.2.176 · Cited by 213 · cited 1×
“For example, for primary or co-primary endpoints in short- to medium-term trials of &3–6 months’ duration, acamprosate was not significantly different from placebo for the percentage of alcohol-free days in a large (n = 592) &6-month study [34] or in a smaller (n = 100) &3-month trial [29], nor was there a statistical…”
BackgroundMASON, B., GOODMAN, A., CHABAC, S., & LEHERT, P. (2006) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2006.02.002 · Cited by 212 · cited 2×
“[34] ACA 2 g/day (253) 56 (&6 months) ACA 3 g/day (82) 61”
BackgroundNeuroprotective and Abstinence-Promoting Effects of Acamprosate: Elucidating the Mechanism of Action
De Witte, P., Littleton, J., Parot, P., & Koob, G. (2005) · CNS Drugs · doi:10.2165/00023210-200519060-00004 · Cited by 201
Combined Efficacy of Acamprosate and Disulfiram in the Treatment of Alcoholism: A Controlled Study
Besson, J., Aeby, F., Kasas, A., Lehert, P., & Potgieter, A. (1998) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.1998.tb04295.x · Cited by 192 · cited 2×
“Most were also double-blind, placebocontrolled trials [42, 43, 45, 47, 48], although two studies used an open-label design, in part, because patients in one of the treatment arms received disulfiram, and patients’ awareness that they are taking disulfiram is an important factor in its effectiveness [44, 46].”
BackgroundResultPelc, I., Verbanck, P., Bon, O. L., Gavrilovic, M., Lion, K., & Lehert, P. (1997) · British Journal of Psychiatry · doi:10.1192/bjp.171.1.73 · Cited by 184
Drugs for relapse prevention of alcoholism: ten years of progress
Spanagel, R., & Kiefer, F. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.12.005 · Cited by 171
Acamprosate Produces Its Anti-Relapse Effects Via Calcium
Spanagel, R., Vengeliene, V., Jandeleit, B., Fischer, W.-N., Grindstaff, K. K., Zhang, X., Gallop, M. A., Krstew, E., Lawrence, A. J., & Kiefer, F. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.264 · Cited by 169 · cited 1×
“Also of interest is a recently reported series of experiments that challenges previous research in this area, suggesting that the pharmacodynamic activity of acamprosate may be related to the calcium salt of acamprosate, which is marketed as acamprosate calcium [20, 21].”
ResultLingford-Hughes, A. R., Welch, S., & Nutt, D. J. (2004) · Journal of Psychopharmacology · doi:10.1177/026988110401800321 · Cited by 167 · cited 1×
“Alcohol dependence develops after repeated alcohol use and is characterized by a strong desire to consume alcohol, difficulties in controlling its use, persisting in its use despite harmful consequences, increased tolerance to its effects, a greater priority given to alcohol consumption than to other activities and ob…”
BackgroundMorley, K. C., Teesson, M., Reid, S. C., Sannibale, C., Thomson, C., Phung, N., Weltman, M., Bell, J. R., Richardson, K., & Haber, P. S. (2006) · Addiction · doi:10.1111/j.1360-0443.2006.01555.x · Cited by 165 · cited 2×
“Most were also double-blind, placebocontrolled trials [42, 43, 45, 47, 48], although two studies used an open-label design, in part, because patients in one of the treatment arms received disulfiram, and patients’ awareness that they are taking disulfiram is an important factor in its effectiveness [44, 46].”
BackgroundResultRammes, G., Mahal, B., Putzke, J., Parsons, C. G., Spielmanns, P., Pestel, E., Spanagel, R., Zieglgänsberger, W., & Schadrack, J. (2001) · Neuropharmacology · doi:10.1016/s0028-3908(01)00008-9 · Cited by 159
Acamprosate: Recent Findings and Future Research Directions
Mann, K., Kiefer, F., Spanagel, R., & Littleton, J. (2008) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2008.00690.x · Cited by 157 · cited 1×
“Acamprosate has been shown to attenuate hyperglutamatergic activity and reduce ethanol consumption in mice that were drinking excessive quantities of ethanol [17, 18], and it reduced glutamate levels (assessed by magnetic resonance spectroscopy) in the brains of alcohol-dependent patients who had been detoxified [19].”
BackgroundTempesta, E. (2000) · Alcohol and Alcoholism · doi:10.1093/alcalc/35.2.202 · Cited by 155 · cited 2×
“Primary outcomes were significantly better with acamprosate than placebo in several other short- to medium-term studies, including the mean cumulative abstinence duration in a smaller (n = 188) 3-month trial [35] and in various larger (n = 262–330) 6-month studies [31, 32, 37], as well as complete abstinence rates in…”
BackgroundLaaksonen, E., Koski-Jännes, A., Salaspuro, M., Ahtinen, H., & Alho, H. (2008) · Alcohol and Alcoholism · doi:10.1093/alcalc/agm136 · Cited by 147 · cited 3×
“Most were also double-blind, placebocontrolled trials [42, 43, 45, 47, 48], although two studies used an open-label design, in part, because patients in one of the treatment arms received disulfiram, and patients’ awareness that they are taking disulfiram is an important factor in its effectiveness [44, 46].”
BackgroundMethodResultThe clinical pharmacology of acamprosate
Kalk, N. J., & Lingford-Hughes, A. R. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12070 · Cited by 147 · cited 3×
“Nevertheless, a body of preclinical evidence suggests that acamprosate may interact with (excitatory) glutamate and (inhibitory) GABA neurotransmission to restore the imbalance between neuronal excitation and inhibition that occurs in chronic alcohol exposure [9, 10].”
BackgroundUmhau, J. C., Momenan, R., Schwandt, M. L., Singley, E., Lifshitz, M., Doty, L., Adams, L. J., Vengeliene, V., Spanagel, R., Zhang, Y., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.125 · Cited by 144 · cited 1×
“Acamprosate has been shown to attenuate hyperglutamatergic activity and reduce ethanol consumption in mice that were drinking excessive quantities of ethanol [17, 18], and it reduced glutamate levels (assessed by magnetic resonance spectroscopy) in the brains of alcohol-dependent patients who had been detoxified [19].”
BackgroundAcamprosate treatment in a long-term community-based alcohol rehabilitation programme
Poldrugo, F. (1997) · Addiction · doi:10.1046/j.1360-0443.1997.9211153713.x · Cited by 134
Pharmacokinetic and Pharmacodynamic Drug Interactions with Ethanol (Alcohol)
Chan, L., & Anderson, G. D. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0190-x · Cited by 130
Harris, B. R., Prendergast, M., Gibson, D. A., Rogers, D. T., Blanchard, J. A., Holley, R. C., Fu, M. C., Hart, S. R., Pedigo, N. W., & Littleton, J. M. (2002) · PubMed · doi:10.1097/01.alc.0000042011.99580.98 · Cited by 124
Clinical Pharmacokinetics of Acamprosate
Saivin, S., Hulot, T., Chabac, S., Potgieter, A., Durbin, P., & Houin, G. (1998) · Clinical Pharmacokinetics · doi:10.2165/00003088-199835050-00001 · Cited by 117 · cited 4×
“Following oral administration and absorption of the drug into the systemic circulation, acamprosate does not undergo metabolism and is excreted unchanged in the urine as acamprosate [9, 25].”
BackgroundInfluentialMann, K., Lemenager, T., Hoffmann, S., Reinhard, I., Hermann, D., Batra, A., Berner, M., Wodarz, N., Heinz, A., Smolka, M. N., et al. (2013) · Addiction Biology · doi:10.1111/adb.12012 · Cited by 116 · cited 12×
“Meta-analysis of four head-to-head studies comparing acamprosate with naltrexone (including COMBINE) found no statistically significant differences between the drugs for any of these outcomes.”
MethodResultInfluentialGual, A. (2001) · Alcohol and Alcoholism · doi:10.1093/alcalc/36.5.413 · Cited by 112 · cited 3×
“Gual and Lehert [32] ACA (141) 35 93** 52**”
BackgroundInfluentialHarris, B. R., Prendergast, M. A., Gibson, D. A., Rogers, D. T., Blanchard, J. A., Holley, R. C., Fu, M. C., Hart, S. R., Pedigo, N. W., & Littleton, J. M. (2002) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2002.tb02484.x · Cited by 110
An open randomized study comparing disulfiram and acamprosate in the treatment of alcohol dependence
DE SOUSA, A., & DE SOUSA, A. (2005) · Alcohol and Alcoholism · doi:10.1093/alcalc/agh187 · Cited by 107
Acamprosate: A Prototypic Neuromodulator in the Treatment of Alcohol Dependence
Mason, B., & Heyser, C. (2010) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152710790966641 · Cited by 103 · cited 11×
“Acamprosate has also been investigated as augmentation therapy in the management of anxiety because of its pharmacodynamic effects of restoring pathological imbalances between neuronal excitation by glutamate and neuronal inhibition by GABA [58, 59].”
BackgroundInfluentialAcamprosate and Prevention of Relapse in Alcoholics
Geerlings, P. J., Ansoms, C., & van den Brink, W. (1997) · European Addiction Research · doi:10.1159/000259166 · Cited by 100 · cited 1×
“Primary outcomes were significantly better with acamprosate than placebo in several other short- to medium-term studies, including the mean cumulative abstinence duration in a smaller (n = 188) 3-month trial [35] and in various larger (n = 262–330) 6-month studies [31, 32, 37], as well as complete abstinence rates in…”
BackgroundKeating, G. M. (2013) · Clinical Drug Investigation · doi:10.1007/s40261-013-0158-x · Cited by 98
Acamprosate for Alcohol Dependence: A Sex‐Specific Meta‐Analysis Based on Individual Patient Data
Mason, B. J., & Lehert, P. (2012) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2011.01616.x · Cited by 94 · cited 1×
“In another large meta-analysis, there were no statistically significant differences in any measure of acamprosate efficacy (or tolerability) between women and men [52].”
BackgroundNew Pharmacological Treatment Strategies for Relapse Prevention
Spanagel, R., & Vengeliene, V. (2012) · Current topics in behavioral neurosciences · doi:10.1007/7854_2012_205 · Cited by 86
Luc, S., Peter, B., Thierry, D., Isabelle, G., Muriel, M., Frédéric, L., & Rémy, L. (2006) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2006.00180.x · Cited by 66 · cited 1×
“nuity and sleep architecture parameters typically disturbed in this population [24].”
BackgroundTHE LONG-TERM COST-EFFECTIVENESS OF IMPROVING ALCOHOL ABSTINENCE WITH ADJUVANT ACAMPROSATE
Palmer, A. J., Neeser, K., Weiss, C., Brandt, A., Comte, S., & Fox, M. (2000) · Alcohol and Alcoholism · doi:10.1093/alcalc/35.5.478 · Cited by 65 · cited 4×
“lifetime) in others [63, 64, 67]; (iii) some included direct costs only [63–65], whereas others considered both direct and indirect (e.”
BackgroundResultInfluentialLejoyeux, M., & Lehert, P. (2011) · Alcohol and Alcoholism · doi:10.1093/alcalc/agq077 · Cited by 64 · cited 1×
“To evaluate the efficacy of acamprosate in alcohol-dependent patients with depression, an individual patient data meta-analysis was conducted from 11 trials with a total of 3354 patients, of whom one-third (n = 1120) had concomitant depression [54].”
MethodDoes Acamprosate Improve Reduction of Drinking As Well As Aiding Abstinence?
Chick, J., Lehert, P., & Landron, F. (2003) · Journal of Psychopharmacology · doi:10.1177/0269881103174017 · Cited by 60 · cited 1×
“Acamprosate reduced the severity of relapse, in particular the overall weekly consumption of alcohol, in an analysis of 15 placebo-controlled trials in which the aim of therapy was complete abstinence [53].”
MethodAnnemans, L., Vanoverbeke, N., Tecco, J. M., & D'Hooghe, D. (2000) · European Addiction Research · doi:10.1159/000019013 · Cited by 51 · cited 3×
“The year of costing ranged from 1995–1997 and the analyses were conducted in Germany [63, 64, 66], Belgium [65] and Spain [67].”
BackgroundMethodPerney, P., Lehert, P., & Mason, B. J. (2012) · Alcohol and Alcoholism · doi:10.1093/alcalc/agr160 · Cited by 48 · cited 1×
“mon problem in alcoholism), which was mainly, although not entirely, related to the effect of the drug on abstinence [41].”
BackgroundThe Cost Effectiveness of Acamprosate in the Treatment of Alcoholism in Germany
Schädlich, P. K., & Brecht, J. G. (1998) · PharmacoEconomics · doi:10.2165/00019053-199813060-00008 · Cited by 47 · cited 4×
“lifetime) in others [63, 64, 67]; (iii) some included direct costs only [63–65], whereas others considered both direct and indirect (e.”
BackgroundResultInfluentialPettorruso, M., De Risio, L., Martinotti, G., Di Nicola, M., Ruggeri, F., Conte, G., Di Giannantonio, M., & Janiri, L. (2014) · BioMed Research International · doi:10.1155/2014/109786 · Cited by 44 · cited 1×
“Pathological gambling is a behavioural addiction, and part of the rationale for considering the glutamatergic drug acamprosate in its management is that the excitatory neurotransmitter glutamate is thought to be involved in the pathophysiology of addictive behaviours [61].”
BackgroundTinnitus treatment with acamprosate: double-blind study
de Azevedo, A. A., & Figueiredo, R. R. (2005) · Brazilian Journal of Otorhinolaryngology · doi:10.1016/s1808-8694(15)31266-0 · Cited by 44 · cited 2×
“Acamprosate has been evaluated in off-label uses for the management of pathological gambling [56, 57], anxiety disorders [58, 59] and tinnitus [60] in small studies with up to 50 patients.”
BackgroundScott, L. J., Figgitt, D. P., Keam, S. J., & Waugh, J. (2005) · CNS Drugs · doi:10.2165/00023210-200519050-00006 · Cited by 41
Pharmacotherapy for Adults With Alcohol-Use Disorders in Outpatient Settings: (553772013-001)
(2013) · PsycEXTRA Dataset · doi:10.1037/e553772013-001 · Cited by 39
Berger, L., FISHER, M. S., Brondino, M. J., Bohn, M. J., Gwyther, R. E., Longo, L. P., Beier, N., Ford, A. L., Greco, J., & Garbutt, J. C. (2012) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.12010 · Cited by 33 · cited 1×
“For example, for primary or co-primary endpoints in short- to medium-term trials of &3–6 months’ duration, acamprosate was not significantly different from placebo for the percentage of alcohol-free days in a large (n = 592) &6-month study [34] or in a smaller (n = 100) &3-month trial [29], nor was there a statistical…”
BackgroundRychlik, R. P. T., Siedentop, H., Pfeil, T. A., & Daniel, D. (2003) · European Addiction Research · doi:10.1159/000068810 · Cited by 31 · cited 5×
“In contrast to the positive findings for naltrexone in COMBINE, a 12-week, randomized, double-blind trial (PREDICT) conducted in 426 alcohol-dependent patients in Germany showed no statistically significant difference between naltrexone, acamprosate or placebo for the primary outcome of heavy drinking relapse rate (Ta…”
BackgroundMethodInfluentialAn Open-Label Trial of Acamprosate in the Treatment of Pathological Gambling
Black, D. W., McNeilly, D. P., Burke, W. J., Shaw, M. C., & Allen, J. (2011) · Annals of Clinical Psychiatry · doi:10.1177/104012371102300403 · Cited by 29 · cited 6×
“In contrast, neither acamprosate (mean dosage 666 mg/day) nor baclofen (mean dosage 30 mg/day) were deemed to be effective in a 6-month, randomized, investigator-blind trial in 17 men with pathological gambling, although the main outcome was complete abstinence [57] (and therefore more difficult to achieve than improv…”
BackgroundInfluentialHiguchi, S., & for the Japanese Acamprosate Study Group (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08940 · Cited by 28
El alcohol y su abuso: impacto socioeconómico
Salvat, M., Ribó, C., Ribas, E., Carrillo, E., Ridao-López, M., & Portella, E. (1998) · Dialnet (Universidad de la Rioja) · Cited by 27
Dannon, P. N., Rosenberg, O., Shoenfeld, N., & Kotler, M. (2011) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2011.00033 · Cited by 26
Pałucha-Poniewiera, A., & Pilc, A. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.05.015 · Cited by 26 · cited 1×
“In a murine model used to evaluate the pharmacodynamic effects of antidepressant agents (tail suppression test), acamprosate produced an antidepressantlike effect that was dependent on NMDA and mGlu5 receptor blockade [23].”
BackgroundUso do acamprosato no tratamento do zumbido: um estudo duplo-cego
de Azevedo, A. A., & Figueiredo, R. R. (2005) · Revista Brasileira de Otorrinolaringologia · doi:10.1590/s0034-72992005000500012 · Cited by 23
Acamprosate Calcium as Augmentation Therapy for Anxiety Disorders
Schwartz, T. L., Siddiqui, U. A., Raza, S., & Costello, A. (2010) · Annals of Pharmacotherapy · doi:10.1345/aph.1p353 · Cited by 22 · cited 9×
“Acamprosate has also been investigated as augmentation therapy in the management of anxiety because of its pharmacodynamic effects of restoring pathological imbalances between neuronal excitation by glutamate and neuronal inhibition by GABA [58, 59].”
BackgroundInfluentialAcamprosate Suppresses Ethanol-Induced Place Preference in Mice With Ethanol Physical Dependence
Kurokawa, K., Mizuno, K., Shibasaki, M., Higashioka, M., Oka, M., Hirouchi, M., & Ohkuma, S. (2013) · Journal of Pharmacological Sciences · doi:10.1254/jphs.13056fp · Cited by 18 · cited 1×
“Acamprosate suppressed alcohol-induced place preference in mice with alcohol physical dependence [22].”
BackgroundA CRITICAL REVIEW OF PHARMACOECONOMIC STUDIES OF ACAMPROSATE
Poldrugo, F., Haeger, D.-A., Comte, S., Walburg, J. A., & Palmer, A. J. (2005) · Alcohol and Alcoholism · doi:10.1093/alcalc/agh171 · Cited by 18 · cited 2×
“analyses) showed that results were most sensitive to changes in abstinence rates [68].”
ResultAcamprosate: An Alcoholism Treatment That May Not Be What We Thought
Heilig, M. A. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2013.272 · Cited by 13 · cited 1×
“Also of interest is a recently reported series of experiments that challenges previous research in this area, suggesting that the pharmacodynamic activity of acamprosate may be related to the calcium salt of acamprosate, which is marketed as acamprosate calcium [20, 21].”
ResultOka, M., Hirouchi, M., Tamura, M., Sugahara, S., & Oyama, T. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.08.014 · Cited by 13 · cited 1×
“Various studies in mice and rats have shown that acamprosate reduces alcohol consumption in rodents that have an extended history of alcohol exposure or are alcohol dependent [8, 15].”
BackgroundOpen-Label Trial of Acamprosate as a Treatment for Anxiety
Hertzman, M., Patt, I. S., & Spielman, L. A. (2009) · The Primary Care Companion to The Journal of Clinical Psychiatry · doi:10.4088/pcc.08l00714 · Cited by 8 · cited 9×
“Acamprosate has also been investigated as augmentation therapy in the management of anxiety because of its pharmacodynamic effects of restoring pathological imbalances between neuronal excitation by glutamate and neuronal inhibition by GABA [58, 59].”
BackgroundMethodInfluentialO2 * FREE ORAL COMMUNICATIONS 2: PHARMACOLOGICAL TREATMENT OF ALCOHOL DEPENDENCE
Lehert, P., Rosner, S., Lehert, P., Rosner, S., Higuchi, S., The Japanese Acamprosate Study Group, Schwejda, C., Krahl, W., Fomino, J., Ridinger, M., et al. (2013) · Alcohol and Alcoholism · doi:10.1093/alcalc/agt098 · Cited by 1
Effect of acamprosate on Sleep Disturbances in Alcoholism: An individual patient data meta-analysis
Perney, P., & Lehert, P. (2013) · Digital Access to Libraries · Cited by 1
Cited by
Analysis of US FDA-Approved Drugs Containing Sulfur Atoms
Scott, K. A., & Njardarson, J. T. (2018) · Topics in Current Chemistry · doi:10.1007/s41061-018-0184-5 · Cited by 1,036
Volkow, N. D., & Blanco, C. (2023) · World psychiatry · doi:10.1002/wps.21073 · Cited by 503
Don’t stress about CRF: assessing the translational failures of CRF1antagonists
Spierling, S. R., & Zorrilla, E. P. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4556-2 · Cited by 170
“analogously, show some efficacy to mitigate alcohol use disorders (see Stevenson et al. 2015; Keating 2013; Rösner et al. 2010; Plosker 2015; but see Palpacuer et al. 2015).”
Medications for alcohol use disorders: An overview
Akbar, M., Egli, M., Cho, Y.-E., Song, B.-J., & Noronha, A. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.11.007 · Cited by 96
“Thus, the use of acamprosate as an adjunct to psychosocial interventions in alcohol-dependent patients provides modest but potentially valuable improvements in alcohol-consumption outcomes (Plosker, 2015).”
Review article: pharmacotherapy for alcohol dependence – the why, the what and the wherefore
Goh, E. T., & Morgan, M. Y. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13965 · Cited by 87
Metadata
- Authors
- Plosker, G. L.
- Affiliations
- Springer Nature (Germany) (DE)
- Corresponding author
- Plosker, Greg L.
- Venue
- Drugs
- Published
- 2015-06-18
- Volume
- 75
- Issue
- 11
- Pages
- 1255-1268
- ISSN
- 0012-6667 (ISSN-L)
- 1179-1950
- OpenAlex
- W637714516
- Semantic Scholar
- 7fbe0bfe4c7b939d7fb97f13c2f968cecf8b6072
- Cited by
- 65
- References
- 67
- Citations by year
- 2026: 5 · 2025: 5 · 2024: 8 · 2023: 9 · 2022: 7 · 2021: 6 · 2020: 4 · 2019: 7 · 2018: 7 · 2017: 5 · 2016: 2
- FWCI
- 3.66
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Drugs (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Health Sciences › Medicine › Clinical Neurology › Alcoholism and Thiamine Deficiency
- Keywords
- acamprosate, alcoholism, alcoholism treatment, pharmacotherapy, psychosocial interventions, abstinence maintenance, naltrexone, drug interactions, liver dysfunction, renal dysfunction, tolerability
- MeSH terms
- Acamprosate, Alcohol Deterrents, Alcoholism, Animals, Dose-Response Relationship, Drug, Drug Interactions, Humans, Taurine, Randomized Controlled Trials as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.